Clinical Laboratory Company Quest Diagnostics Agrees to Acquire Celera Corp. for $657 Million

Mar 21, 2011 | Laboratory Operations, Laboratory Pathology

Celera is not a medical laboratory, but develops biomarkers and molecular diagnostics tests For the second time since the New Year, Quest Diagnostics Incorporated (NYSE:DGX) has announced an acquisition. Last Friday, Quest Diagnostics said it had agreed to purchase Celera Corp. (NASDAQ:CRA) for a purchase price that Reuters reported to be $657 million. What makes this acquisition different from those typically done by Quest Diagnostics and its major competitor, Laboratory Corporation of...
;